Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Mahoney

Clinical Cardiac Electrophysiology Omaha, NE Medical Doctor

NPI 1245291236 CMS profile 192017

1120 N 103Rd Plz, Suite 100, Omaha, NE 68114

Open in the dashboard

General payments

$117,767

546 records reported · program years 2019–2025

Research payments

$500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,600 paid to institutions, not to them · program year 2019

Through program year 2025, Jeffrey Mahoney of Omaha, NE is reported in the CMS Open Payments database as having received $117,767 across 546 general payments and $500 in research payments paid to them. Separately, studies naming them as principal investigator received $1,600 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,420 36
2024 General $4,588 69
2023 General $2,710 66
2022 General $3,338 75
2021 General $3,507 69
2020 General $37,484 89
2020 Research $500 1
2019 General $64,719 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Mahoney
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jeffrey Mahoney were reported at $1,420. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jeffrey Mahoney Clinical Cardiac Electrophysiology median Middle half National median
2019 $64,719 $2,361 $585–$8,260 $163
2020 $37,484 $993 $247–$4,351 $114
2021 $3,507 $1,185 $326–$4,739 $132
2022 $3,338 $2,073 $554–$6,789 $149
2023 $2,710 $2,568 $759–$8,159 $160
2024 $4,588 $2,557 $703–$7,403 $164
2025 $1,420 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $67,179 69 payments
  2. E.R. Squibb & Sons, L.L.C. $28,614 38 payments
  3. Abbott Laboratories $14,623 216 payments
  4. Medtronic, Inc. $2,573 26 payments
  5. Atricure, Inc. $1,101 8 payments
  6. Novartis Pharmaceuticals Corporation $801 55 payments
  7. Amgen Inc. $486 35 payments
  8. AstraZeneca Pharmaceuticals LP $435 7 payments
  9. Sanofi-Aventis U.S. LLC $270 18 payments
  10. Boston Scientific Corporation $255 7 payments
  11. Other $1,430 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90,375 34 payments
  2. Food and Beverage $21,525 487 payments
  3. Travel and Lodging $5,367 24 payments
  4. Consulting Fee $500 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $67,103 64 payments
  2. ELIQUIS Cardiovascular $28,558 35 payments
  3. AVEIR Cardiac Rhythm Management $2,264 26 payments
  4. Quadra Assura CRT Defibrillator Cardiac Arrhythmias and Heart Failure $1,788 20 payments
  5. Confirm Rx $1,270 16 payments
  6. QUADRA ASSURA $1,209 22 payments
  7. AVEIR Cardiac Rhythm Management $1,019 14 payments
  8. QUADRA ALLURE MP $967 16 payments
  9. Quadra Allure MP RF CRT Pacemkr $919 16 payments
  10. Quadra Assura CRT Defibrillator Cardiac Rhythm Management $743 10 payments
  11. Other $11,209 337 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abbott Laboratories $500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

4,096

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,216,909

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

41.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 920 $878,823
Xarelto Rivaroxaban Brand 159 $157,077
Multaq Dronedarone Hcl Brand 59 $89,448
Flecainide Acetate Generic 678 $32,565
Entresto Sacubitril/Valsartan Brand 18 $13,001
Dofetilide Generic 78 $12,782
Amiodarone Hcl Generic 689 $10,999
Metoprolol Succinate Generic 488 $5,344
Sotalol Sotalol Hcl Brand 364 $5,141
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 142 $3,995

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$305,989

Medicare's payments for the services billed

Medicare patients

1,840

Average age 78

Services billed

7,290

929 women, 911 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 65%
Arthritis 51%
Ischemic heart disease 40%
Heart failure 36%
Chronic kidney disease 34%
Diabetes 27%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $149
$149 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $86
$86 18 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $57
$57 — —
Repatha
  • Amgen Inc. $33
$33 — —
EDARBI
  • CutisPharma, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

547 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record